AR 709

Drug Profile

AR 709

Alternative Names: AR-709

Latest Information Update: 23 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arpida
  • Developer Evolva Holding SA
  • Class Antibacterials; Diaminopyrimidines
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Respiratory tract infections

Most Recent Events

  • 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA
  • 16 Jul 2008 Preclinical development is ongoing
  • 02 Oct 2007 Preclinical trials in Respiratory tract infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top